Suppr超能文献

打破淀粉样蛋白假象:阿尔茨海默病发病机制的微生物谜团——从肠道微生物群和病毒到脑生物膜

Shattering the Amyloid Illusion: The Microbial Enigma of Alzheimer's Disease Pathogenesis-From Gut Microbiota and Viruses to Brain Biofilms.

作者信息

Onisiforou Anna, Charalambous Eleftheria G, Zanos Panos

机构信息

Translational Neuropharmacology Laboratory, Department of Psychology, University of Cyprus, 75 Kallipoleos Avenue, 1678 Nicosia, Cyprus.

Center of Applied Neuroscience, 75 Kallipoleos Avenue, 1678 Nicosia, Cyprus.

出版信息

Microorganisms. 2025 Jan 5;13(1):90. doi: 10.3390/microorganisms13010090.

Abstract

For decades, Alzheimer's Disease (AD) research has focused on the amyloid cascade hypothesis, which identifies amyloid-beta (Aβ) as the primary driver of the disease. However, the consistent failure of Aβ-targeted therapies to demonstrate efficacy, coupled with significant safety concerns, underscores the need to rethink our approach to AD treatment. Emerging evidence points to microbial infections as environmental factors in AD pathoetiology. Although a definitive causal link remains unestablished, the collective evidence is compelling. This review explores unconventional perspectives and emerging paradigms regarding microbial involvement in AD pathogenesis, emphasizing the gut-brain axis, brain biofilms, the oral microbiome, and viral infections. Transgenic mouse models show that gut microbiota dysregulation precedes brain Aβ accumulation, emphasizing gut-brain signaling pathways. Viral infections like Herpes Simplex Virus Type 1 (HSV-1) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may lead to AD by modulating host processes like the immune system. Aβ peptide's antimicrobial function as a response to microbial infection might inadvertently promote AD. We discuss potential microbiome-based therapies as promising strategies for managing and potentially preventing AD progression. Fecal microbiota transplantation (FMT) restores gut microbial balance, reduces Aβ accumulation, and improves cognition in preclinical models. Probiotics and prebiotics reduce neuroinflammation and Aβ plaques, while antiviral therapies targeting HSV-1 and vaccines like the shingles vaccine show potential to mitigate AD pathology. Developing effective treatments requires standardized methods to identify and measure microbial infections in AD patients, enabling personalized therapies that address individual microbial contributions to AD pathogenesis. Further research is needed to clarify the interactions between microbes and Aβ, explore bacterial and viral interplay, and understand their broader effects on host processes to translate these insights into clinical interventions.

摘要

几十年来,阿尔茨海默病(AD)的研究一直聚焦于淀粉样蛋白级联假说,该假说将β-淀粉样蛋白(Aβ)确定为该疾病的主要驱动因素。然而,以Aβ为靶点的治疗方法始终未能证明其有效性,再加上严重的安全问题,这凸显了我们需要重新思考AD的治疗方法。新出现的证据表明,微生物感染是AD病理病因中的环境因素。尽管尚未确定明确的因果关系,但综合证据很有说服力。本综述探讨了关于微生物参与AD发病机制的非常规观点和新出现的范式,重点强调了肠-脑轴、脑生物膜、口腔微生物群和病毒感染。转基因小鼠模型表明,肠道微生物群失调先于脑Aβ积累,强调了肠-脑信号通路。单纯疱疹病毒1型(HSV-1)和严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)等病毒感染可能通过调节免疫系统等宿主过程导致AD。Aβ肽作为对微生物感染的一种抗菌功能可能会无意中促进AD。我们讨论了基于微生物群的潜在治疗方法,认为这是管理并可能预防AD进展的有前景的策略。粪便微生物群移植(FMT)可恢复肠道微生物平衡,减少Aβ积累,并改善临床前模型中的认知能力。益生菌和益生元可减轻神经炎症和Aβ斑块,而针对HSV-1的抗病毒疗法和带状疱疹疫苗等疫苗显示出减轻AD病理的潜力。开发有效的治疗方法需要标准化的方法来识别和测量AD患者中的微生物感染,从而实现针对个体微生物对AD发病机制的影响的个性化治疗。需要进一步研究来阐明微生物与Aβ之间的相互作用,探索细菌和病毒的相互作用,并了解它们对宿主过程的更广泛影响,以便将这些见解转化为临床干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45bd/11767882/46298aa71522/microorganisms-13-00090-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验